Design Therapeutics (NASDAQ:DSGN) Shares Up 1.3% - Should You Buy?

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) shares rose 1.3% on Monday . The company traded as high as $5.60 and last traded at $5.40. Approximately 154,551 shares traded hands during mid-day trading, an increase of 33% from the average daily volume of 116,630 shares. The stock had previously closed at $5.33.

Design Therapeutics Price Performance

The stock's 50 day simple moving average is $4.16 and its two-hundred day simple moving average is $4.09. The stock has a market cap of $299.56 million, a P/E ratio of -4.70 and a beta of 1.58.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.02). As a group, analysts forecast that Design Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Design Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. ProShare Advisors LLC acquired a new position in shares of Design Therapeutics in the fourth quarter valued at about $71,000. Invesco Ltd. acquired a new stake in Design Therapeutics during the fourth quarter worth about $71,000. Los Angeles Capital Management LLC acquired a new stake in Design Therapeutics during the second quarter worth about $43,000. Velan Capital Investment Management LP acquired a new stake in Design Therapeutics during the first quarter worth about $54,000. Finally, Jane Street Group LLC acquired a new stake in Design Therapeutics during the first quarter worth about $70,000. 56.64% of the stock is currently owned by institutional investors and hedge funds.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.